{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:43:20Z","timestamp":1792100600099,"version":"4.4.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,2,14]],"date-time":"2006-02-14T00:00:00Z","timestamp":1139875200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1007\/s00228-006-0096-0","type":"journal-article","created":{"date-parts":[[2006,2,13]],"date-time":"2006-02-13T11:29:40Z","timestamp":1139830180000},"page":"225-233","source":"Crossref","is-referenced-by-count":130,"title":["Hyperforin in St. John\u2019s wort drug interactions"],"prefix":"10.1007","volume":"62","author":[{"given":"Rajanikanth","family":"Madabushi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Drewelow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Derendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Butterweck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,2,14]]},"reference":[{"issue":"1","key":"96_CR1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF02850017","volume":"19","author":"K Behnke","year":"2002","unstructured":"Behnke K, Jensen GS, Graubaum HJ, Gruenwald J (2002) Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Adv Ther 19(1):43\u201352","journal-title":"Adv Ther"},{"issue":"1","key":"96_CR2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00406-004-0532-z","volume":"255","author":"L Bjerkenstedt","year":"2005","unstructured":"Bjerkenstedt L, Edman GV, Alken RG, Mannel M (2005) Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients. Eur Arch Psychiatry Clin Neurosci 255(1):40\u201347","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"2","key":"96_CR3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00004850-200015020-00001","volume":"15","author":"E Schrader","year":"2000","unstructured":"Schrader E (2000) Equivalence of St John\u2019s wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 15(2):61\u201368","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"96_CR4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0149-2918(00)89010-4","volume":"22","author":"R Brenner","year":"2000","unstructured":"Brenner R, Azbel V, Madhusoodanan S, Pawlowska M (2000) Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin Ther 22(4):411\u2013419","journal-title":"Clin Ther"},{"issue":"2","key":"96_CR5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1055\/s-2005-837807","volume":"38","author":"M Gastpar","year":"2005","unstructured":"Gastpar M, Singer A, Zeller K (2005) Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry 38(2):78\u201386","journal-title":"Pharmacopsychiatry"},{"issue":"7224","key":"96_CR6","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1136\/bmj.319.7224.1534","volume":"319","author":"M Philipp","year":"1999","unstructured":"Philipp M, Kohnen R, Hiller KO (1999) Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. BMJ 319(7224):1534\u20131538","journal-title":"BMJ"},{"issue":"7260","key":"96_CR7","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/bmj.321.7260.536","volume":"321","author":"H Woelk","year":"2000","unstructured":"Woelk H (2000) Comparison of St John\u2019s wort and imipramine for treating depression: randomised controlled trial. BMJ 321(7260):536\u2013539","journal-title":"BMJ"},{"issue":"5","key":"96_CR8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1078\/09447110260571742","volume":"9","author":"V Schulz","year":"2002","unstructured":"Schulz V (2002) Clinical trials with hypericum extracts in patients with depression\u2013results, comparisons, conclusions for therapy with antidepressant drugs. Phytomedicine 9(5):468\u2013474","journal-title":"Phytomedicine"},{"issue":"8","key":"96_CR9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/00023210-200317080-00001","volume":"17","author":"V Butterweck","year":"2003","unstructured":"Butterweck V (2003) Mechanism of action of St John\u2019s wort in depression: what is known? CNS Drugs 17(8):539\u2013562","journal-title":"CNS Drugs"},{"issue":"49","key":"96_CR10","first-page":"56","volume":"138","author":"M Melzer","year":"1998","unstructured":"Melzer M, Fuhrken D, Kolkmann R (1998) Hyperforin im Johanniskraut. Dt Apoth Ztg 138(49):56\u201362","journal-title":"Dt Apoth Ztg"},{"key":"96_CR11","first-page":"97","volume":"30","author":"A Brattstroem","year":"2002","unstructured":"Brattstroem A (2002) Der Johanniskrautextrakt ZE 117: Wirksamkeit und Sicherheit. DAZ 30:97\u201399","journal-title":"DAZ"},{"key":"96_CR12","unstructured":"Willmar Schwabe GC (1997) Stable extract of Hypericum perforatum L., process for preparing the same and pharmaceutical composition. International Patent, WO 97\/13489"},{"key":"96_CR13","unstructured":"Willmar Schwabe GC (1998) Stable extract of Hypericum perforatum L., a method for producing the same, and corresponding pharmaceutical preparations. International Patent, WO 98\/44936"},{"issue":"4","key":"96_CR14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1055\/s-2005-864099","volume":"71","author":"G Arold","year":"2005","unstructured":"Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin HH, Friede M, Roots I (2005) No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John\u2019s wort extract. Planta Med 71(4):331\u2013337","journal-title":"Planta Med"},{"key":"96_CR15","doi-asserted-by":"crossref","unstructured":"Mai I, Bauer S, Perloff E, Johne A, Uehleke B, Frank B, Budde K, Roots I (2004) Hyperforin content determines the magnitude of the St. John\u2019s wort-cyclosporine drug interaction. Clin Pharmacol Ther in press","DOI":"10.1016\/j.clpt.2004.07.004"},{"issue":"11","key":"96_CR16","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2165\/00002018-200427110-00003","volume":"27","author":"M Mannel","year":"2004","unstructured":"Mannel M (2004) Drug interactions with St John\u2019s wort: mechanisms and clinical implications. Drug Saf 27(11):773\u2013797","journal-title":"Drug Saf"},{"issue":"2","key":"96_CR17","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/0269881104042632","volume":"18","author":"S Zhou","year":"2004","unstructured":"Zhou S, Chan E, Pan SQ, Huang M, Lee EJ (2004) Pharmacokinetic interactions of drugs with St John\u2019s wort. J Psychopharmacol 18(2):262\u2013276","journal-title":"J Psychopharmacol"},{"key":"96_CR18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/j.1875-9114.1998.tb03830.x","volume":"18","author":"E Landrum-Michalets","year":"1998","unstructured":"Landrum-Michalets E (1998) Update: clinically significant cytochrome P450 drug interactions. Pharmacotherapy 18:84\u2013112","journal-title":"Pharmacotherapy"},{"key":"96_CR19","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/004982598238859","volume":"28","author":"DA Smith","year":"1998","unstructured":"Smith DA, Abel SM, Hyland R, Jones BC (1998) Human cytochrome P450\u2019s: selectivity and measurment in vivo. Xenobiotica 28:1095\u20131128","journal-title":"Xenobiotica"},{"key":"96_CR20","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1080\/004982598238868","volume":"28","author":"S Smith","year":"1998","unstructured":"Smith S, Stubbins MJ, Harries LW, Wolf CR (1998) Molecular genetics of human cytochrome P450 monooxygenase superfamily. Xenobiotica 28:1129\u20131165","journal-title":"Xenobiotica"},{"issue":"11","key":"96_CR21","first-page":"441","volume":"29","author":"T Bienvenu","year":"1991","unstructured":"Bienvenu T, Rey E, Pons G, d\u2019Athis P, Olive G (1991) A simple non-invasive procedure for the investigation of cytochrome P-450 IIIA dependent enzymes in humans. Int J Clin Pharmacol Ther Toxicol 29(11):441\u2013445","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"issue":"4","key":"96_CR22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0031-6989(87)90084-1","volume":"19","author":"P Dolara","year":"1987","unstructured":"Dolara P, Lodovici M, Salvadori M, Zaccara G, Muscas GC (1987) Urinary 6-beta-OH-cortisol and paracetamol metabolites as a probe for assessing oxidation and conjugation of chemicals in humans. Pharmacol Res Commun 19(4):261\u2013273","journal-title":"Pharmacol Res Commun"},{"issue":"4","key":"96_CR23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2125.1989.tb03516.x","volume":"28","author":"C Ged","year":"1989","unstructured":"Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Bories P, Michel H, Beaune P, Maurel P (1989) The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 28(4):373\u2013387","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"96_CR24","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1067\/mcp.2000.106793","volume":"67","author":"CA Roby","year":"2000","unstructured":"Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH (2000) St John\u2019s Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 67(5):451\u2013457","journal-title":"Clin Pharmacol Ther"},{"key":"96_CR25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1054-3589(08)60934-5","volume":"24","author":"ZC Gatmaitan","year":"1993","unstructured":"Gatmaitan ZC, Arias IM (1993) Structure and function of P-glycoprotein in normal liver and small intestine. Adv Pharmacol 24:77\u201397","journal-title":"Adv Pharmacol"},{"key":"96_CR26","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0009-9236(97)90027-8","volume":"62","author":"KS Lown","year":"1997","unstructured":"Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB (1997) Role of intestinal P-glycoprotein(mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62:248\u2013260","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"96_CR27","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1067\/mcp.2000.112240","volume":"68","author":"D Durr","year":"2000","unstructured":"Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K (2000) St John\u2019s Wort induces intestinal P-glycoprotein\/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68(6):598\u2013604","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"96_CR28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0009-9236(01)00127-8","volume":"70","author":"Z Wang","year":"2001","unstructured":"Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD (2001) The effects of St John\u2019s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 70(4):317\u2013326","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"96_CR29","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/cp.1999.v66.a101944","volume":"66","author":"A Johne","year":"1999","unstructured":"Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St John\u2019s wort (Hypericum perforatum). Clin Pharmacol Ther 66(4):338\u2013345","journal-title":"Clin Pharmacol Ther"},{"issue":"9203","key":"96_CR30","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(99)05712-8","volume":"355","author":"SC Piscitelli","year":"2000","unstructured":"Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J (2000) Indinavir concentrations and St John\u2019s wort. Lancet 355(9203):547\u2013548","journal-title":"Lancet"},{"issue":"9203","key":"96_CR31","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0140-6736(99)05467-7","volume":"355","author":"F Ruschitzka","year":"2000","unstructured":"Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G (2000) Acute heart transplant rejection due to Saint John\u2019s wort [letter] [see comments]. Lancet 355(9203):548\u2013549","journal-title":"Lancet"},{"issue":"1","key":"96_CR32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0022-3565(24)39043-3","volume":"294","author":"RS Obach","year":"2000","unstructured":"Obach RS (2000) Inhibition of human cytochrome P450 enzymes by constituents of St. John\u2019s Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 294(1):88\u201395","journal-title":"J Pharmacol Exp Ther"},{"key":"96_CR33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.0306-5251.2001.01516.x","volume":"53","author":"M Hennessy","year":"2002","unstructured":"Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D, Mulcahy F, Feely J (2002) St John\u2019s Wort increases expression of P-glycoprotein: Implications for drug interactions. Br J Clin Pharmacol 53:75\u201382","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"96_CR34","doi-asserted-by":"crossref","first-page":"L133","DOI":"10.1016\/S0024-3205(99)00659-1","volume":"66","author":"JS Markowitz","year":"2000","unstructured":"Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z, Risch SC (2000) Effect of St. John\u2019s wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 66(9):L133\u2013L139","journal-title":"Life Sci"},{"issue":"1","key":"96_CR35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.clpt.2005.01.024","volume":"78","author":"J Rengelshausen","year":"2005","unstructured":"Rengelshausen J, Banfield M, Riedel KD, Burhenne J, Weiss J, Thomsen T, Walter-Sack I, Haefeli WE, Mikus G (2005) Opposite effects of short-term and long-term St John\u2019s wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 78(1):25\u201333","journal-title":"Clin Pharmacol Ther"},{"issue":"15","key":"96_CR36","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.2165\/00003495-200161150-00002","volume":"61","author":"AA Izzo","year":"2001","unstructured":"Izzo AA, Ernst E (2001) Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 61(15):2163\u20132175","journal-title":"Drugs"},{"issue":"7456","key":"96_CR37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/bmj.329.7456.27","volume":"329","author":"E Mills","year":"2004","unstructured":"Mills E, Montori VM, Wu P, Gallicano K, Clarke M, Guyatt G (2004) Interaction of St John\u2019s wort with conventional drugs: systematic review of clinical trials. BMJ 329(7456):27\u201330","journal-title":"BMJ"},{"issue":"9195","key":"96_CR38","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1016\/S0140-6736(99)00418-3","volume":"354","author":"E Ernst","year":"1999","unstructured":"Ernst E (1999) Second thoughts about safety of St John\u2019s wort. Lancet 354(9195):2014\u20132016","journal-title":"Lancet"},{"key":"96_CR39","unstructured":"Medical Products Agency, Sweden. St John\u2019s Wort may influence other medications. In; 2002"},{"key":"96_CR40","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1046\/j.1365-2125.2003.01716.x","volume":"55","author":"UI Schwarz","year":"2003","unstructured":"Schwarz UI, Buschel B, Kirch W (2003) Unwanted pregnancy on self medication with St John\u2019s Wort despite hormonal contraception. Br J Clin Pharmacol 55:112\u2013113","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"96_CR41","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.clpt.2003.08.009","volume":"74","author":"SD Hall","year":"2003","unstructured":"Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC (2003) The interaction between St John\u2019s wort and an oral contraceptive. Clin Pharmacol Ther 74(6):525\u2013535","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"96_CR42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.contraception.2004.11.004","volume":"71","author":"PA Murphy","year":"2005","unstructured":"Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL (2005) Interaction of St. John\u2019s Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 71(6):402\u2013408","journal-title":"Contraception"},{"issue":"6","key":"96_CR43","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1046\/j.1365-2125.2003.02005.x","volume":"56","author":"A Pfrunder","year":"2003","unstructured":"Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J (2003) Interaction of St John\u2019s wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 56(6):683\u2013690","journal-title":"Br J Clin Pharmacol"},{"key":"96_CR44","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/0024-3205(90)90431-P","volume":"47","author":"FP Guengerich","year":"1990","unstructured":"Guengerich FP (1990) Metabolism of 17 alpha-ethinyl estradiol in humans. Life Sci 47:1981\u20131988","journal-title":"Life Sci"},{"key":"96_CR45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00004714-200004000-00001","volume":"20","author":"RI Shader","year":"2000","unstructured":"Shader RI, Oesterheld JR (2000) Contraceptive effectiveness: cytochromes and induction. J Clin Psychopharmacol 20:119\u2013121","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"96_CR46","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/j.1875-9114.1998.tb03161.x","volume":"18","author":"L Shane-McWhorter","year":"1998","unstructured":"Shane-McWhorter L, Cerveny JD, MacFarlane LL, Osborn C (1998) Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy. Pharmacotherapy 18(6):1360\u20131364","journal-title":"Pharmacotherapy"},{"issue":"6","key":"96_CR47","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/0010-7824(86)90044-2","volume":"33","author":"M Haukkamaa","year":"1986","unstructured":"Haukkamaa M (1986) Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment. Contraception 33(6):559\u2013565","journal-title":"Contraception"},{"issue":"3","key":"96_CR48","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0010-7824(86)90018-1","volume":"33","author":"V Odlind","year":"1986","unstructured":"Odlind V, Olsson SE (1986) Enhanced metabolism of levonorgestrel during phenytoin treatment in a woman with Norplant implants. Contraception 33(3):257\u2013261","journal-title":"Contraception"},{"issue":"3","key":"96_CR49","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0022-3565(24)37890-5","volume":"287","author":"DM Gentile","year":"1998","unstructured":"Gentile DM, Verhoeven CH, Shimada T, Back DJ (1998) The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther 287(3):975\u2013982","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"96_CR50","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1067\/mcp.2000.111530","volume":"68","author":"AH Burstein","year":"2000","unstructured":"Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W (2000) Lack of effect of St John\u2019s Wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 68(6):605\u2013612","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"96_CR51","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00008571-199204000-00004","volume":"2","author":"L Gu","year":"1992","unstructured":"Gu L, Gonzalez FJ, Kalow W, Tang BK (1992) Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 2(2):73\u201377","journal-title":"Pharmacogenetics"},{"issue":"26","key":"96_CR52","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1016\/S0024-3205(02)01566-7","volume":"70","author":"AR Bilia","year":"2002","unstructured":"Bilia AR, Gallori S, Vincieri FF (2002) St. John\u2019s wort and depression: efficacy, safety and tolerability-an update. Life Sci 70(26):3077\u20133096","journal-title":"Life Sci"},{"issue":"6","key":"96_CR53","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2165\/00002512-199915060-00002","volume":"15","author":"E Ernst","year":"1999","unstructured":"Ernst E (1999) Herbal medications for common ailments in the elderly. Drugs Aging 15(6):423\u2013428","journal-title":"Drugs Aging"},{"issue":"4","key":"96_CR54","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2125.2002.01683.x","volume":"54","author":"L Henderson","year":"2002","unstructured":"Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P (2002) St John\u2019s wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 54(4):349\u2013356","journal-title":"Br J Clin Pharmacol"},{"key":"96_CR55","first-page":"202","volume":"33","author":"A Nebel","year":"1998","unstructured":"Nebel A, Schneider BJ, Baker RK, Kroll DJ (1998) Potential metabolic interaction between St John\u2019s Wort and theophylline. Ann Pharmacother 33:202","journal-title":"Ann Pharmacother"},{"issue":"1","key":"96_CR56","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/0091270003261496","volume":"44","author":"T Morimoto","year":"2004","unstructured":"Morimoto T, Kotegawa T, Tsutsumi K, Ohtani Y, Imai H, Nakano S (2004) Effect of St. John\u2019s wort on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol 44(1):95\u2013101","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"96_CR57","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1124\/dmd.32.5.512","volume":"32","author":"BJ Komoroski","year":"2004","unstructured":"Komoroski BJ, Zhang S, Cai H, Hutzler JM, Frye R, Tracy TS, Strom SC, Lehmann T, Ang CY, Cui YY, Venkataramanan R (2004) Induction and inhibition of cytochromes P450 by the St. John\u2019s wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 32(5):512\u2013518","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"96_CR58","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/oxfordjournals.eurheartj.a060485","volume":"15","author":"A Keech","year":"1994","unstructured":"Keech A, Collins R, MacMahon S, Armitage J, Lawson A, Wallendszus K, Fatemian M, Kearney E, Lyon V, Mindell J, et al (1994) Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 15(2):255\u2013269","journal-title":"Eur Heart J"},{"issue":"1","key":"96_CR59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0163-7258(98)00016-3","volume":"80","author":"U Christians","year":"1998","unstructured":"Christians U, Jacobsen W, Floren LC (1998) Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 80(1):1\u201334","journal-title":"Pharmacol Ther"},{"issue":"4","key":"96_CR60","first-page":"476","volume":"18","author":"S Vickers","year":"1990","unstructured":"Vickers S, Duncan CA, Vyas KP, Kari PH, Arison B, Prakash SR, Ramjit HG, Pitzenberger SM, Stokker G, Duggan DE (1990) In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 18(4):476\u2013483","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"96_CR61","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1067\/mcp.2001.120025","volume":"70","author":"K Sugimoto","year":"2001","unstructured":"Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakamoto K, Masada M, Miyamori I, Fujimura A (2001) Different effects of St John\u2019s wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 70(6):518\u2013524","journal-title":"Clin Pharmacol Ther"},{"issue":"13","key":"96_CR62","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1073\/pnas.130155097","volume":"97","author":"LB Moore","year":"2000","unstructured":"Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, Kliewer SA (2000) St. John\u2019s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97(13):7500\u20137502","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"96_CR63","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/toxsci\/kfg174","volume":"75","author":"L Cantoni","year":"2003","unstructured":"Cantoni L, Rozio M, Mangolini A, Hauri L, Caccia S (2003) Hyperforin contributes to the hepatic CYP3A-inducing effect of Hypericum perforatum extract in the mouse. Toxicol Sci 75(1):25\u201330","journal-title":"Toxicol Sci"},{"issue":"5","key":"96_CR64","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0024-3205(03)00314-X","volume":"73","author":"V Butterweck","year":"2003","unstructured":"Butterweck V, Christoffel V, Nahrstedt A, Petereit F, Spengler B, Winterhoff H (2003) Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models. Life Sci 73(5):627\u2013639","journal-title":"Life Sci"},{"issue":"Suppl 1","key":"96_CR65","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1055\/s-2007-979346","volume":"31","author":"G Laakmann","year":"1998","unstructured":"Laakmann G, Schule C, Baghai T, Kieser M (1998) St. John\u2019s wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 31 Suppl 1:54\u201359","journal-title":"Pharmacopsychiatry"},{"key":"96_CR66","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/(SICI)1099-1077(199804)13:3<163::AID-HUP5>3.0.CO;2-I","volume":"13","author":"E Schrader","year":"1998","unstructured":"Schrader E, Meier B, Brattstrom A (1998) Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study. Human Psychopharmacol 13:163\u2013169","journal-title":"Human Psychopharmacol"},{"issue":"2","key":"96_CR67","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.clpt.2004.12.031","volume":"77","author":"SC Mueller","year":"2005","unstructured":"Mueller SC, Majcher-Peszynska J, Klammt S, Uehleke B, Miekisch B, Kundt G, Drewelow B (2005) Induction of CYP3A by St. Johns Wort (SJW) depends on hyperforin (HYF) dose ABSTRACT. Clin Pharmacol Ther 77(2):P36","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-006-0096-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-006-0096-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-006-0096-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T13:35:46Z","timestamp":1736256946000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-006-0096-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,14]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["96"],"URL":"https:\/\/doi.org\/10.1007\/s00228-006-0096-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,14]]}}}